Page 1

MEDIVIR • • MEDIVIR AB – INTERIM REPORT JANUARY – MARCH 2021 - - Financing secured to bring the MIV - 818 study into the next phase January - March Financial summary for the quarter • Net turnover amounted to SEK 9.9 ( 7.3 ) million . The loss before interest , tax , depreciation and amortization ( EBITDA ) amounted to SEK -7.2 ( -20.7 ) million . Basic and diluted earnings per share amounted to SEK -0.18 ( -0.96 ) and SEK -0.18 ( -0.96 ) respectively . • Cash flow from operating activities amounted to SEK -1.5 ( -16.6 ) million . • Liquid assets and short - term investments at the end of the period amounted to SEK 269.3 ( 116.6 ) million . Significant events during the quarter • In January the company signed an exclusive license agreement with IGM Biosciences , Inc. for birinapant . Medivir received a payment of USD 1 million after signing , which is to be followed by an additional USD 1.5 million when IGM includes birinapant in phase I clinical trials . In addition , the agreement entitles Medivir to milestone payments and royalties . A rights issue of class B shares with preferential rights for existing shareholders was completed in early February . Through the rights issue , which was oversubscribed to 93.5 percent , Medivir received approximately SEK 170 million before transaction costs . The Board of Directors decided to exercise the over- allotment option of SEK 25 million , directed to the specialist investor HealthInvest . An Extraordinary General Meeting on March 11 , 2021 , decided on a directed new share issue of approximately SEK 28 million to Linc AB . • • In February 2021 a licensing agreement with Ubiquigent was signed for the preclinical research program USP7 . In March , the last patient was included in the first part of the phase lb study with MIV - 818 . In March 2021 , it was announced that Yilmaz Mahshid will leave his position as CEO of Medivir at the Annual General Meeting on May 5 , for personal reasons . The recruitment process for a new CEO has begun . Medivir's Nomination Committee proposes the re- election of Uli Hacksell , Lennart Hansson , An van Es Johansson and Bengt Westermark as board members . The Nomination Committee proposes the election of Yilmaz Mahshid as new board member and that Uli Hacksell is elected Chairman of the Board . Bengt Julander and Helena Levander have declined re - election . Significant events after the end of the quarter On April 16 , it was announced that Magnus Christensen had been appointed interim CEO of Medivir . He will take up his new role in connection with Medivir's Annual General Meeting on May 5 , 2021 . • On April 19 , it was announced that the overall results from the first part of the phase lb study with MIV - 818 were positive with a good safety and tolerability profile . Thus , the starting dose for the second part of the phase lb study could be determined . Medivir in brief Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high . The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients . Medivir is focusing on the development of MIV - 818 , a pro - drug designed to selectively treat liver cancer cells and to minimize side effects . Collaborations and partnerships are important parts of Medivir's business model , and the drug development is conducted either by Medivir or in partnership . Birinapant , a SMAC mimetic , is exclusively outlicensed to IGM Biosciences ( Nasdaq : IGMS ) to be developed in combination with IGM - antibodies for the treatment of solid tumors . Medivir's share ( ticker : MVIR ) is listed on Nasdaq Stockholm's Small Cap list . www.medivir.com Medivir AB ( publ ) , 556238-4361 . PO Box 1086 , SE - 141 22 Huddinge , Sweden . Telephone +46 ( 0 ) 8-5468 3100 . info@medivir.se | www.medivir.com 1